MiNK Therapeutics, Inc.
As of Oct 22, 2026, MiNK Therapeutics is in Stage 2, the uptrend phase, now in week 4 (since Sep 29, 2026). It closed at $10.06, 32.8% below its 52-week high and below its 200-day average, which is falling.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural kille… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is INKT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INKT among Biotechnology291st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …291 | INKT | Stage 2 · wk 4 | 32 | −18.5% |
MiNK Therapeutics: quick answers
What stage is MiNK Therapeutics in?
As of Oct 22, 2026, MiNK Therapeutics (INKT) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 29, 2026 and is in week 4. What the four stages mean
Is MiNK Therapeutics in an uptrend?
Yes. MiNK Therapeutics is in a Stage 2 uptrend. It trades 11.3% below its 200-day average, which is falling.
How far is MiNK Therapeutics from its 52-week high?
MiNK Therapeutics closed at $10.06 on Oct 22, 2026, 32.8% below its 52-week high of $14.98. Its 52-week low is $8.56.
How has MiNK Therapeutics performed over the past year?
As of Oct 22, 2026, MiNK Therapeutics is down 32.3% over the past year and down 9.5% so far in 2026.
Which sector and industry is MiNK Therapeutics in?
MiNK Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.